title: [Zoledronate inhibits TRPV5 and NFATc1 expression during differentiation of osteoclasts].
abstract: OBJECTIVE
  To explore the effect of zoledronate (ZOL) on osteoclast differentiation and expressions of transient receptor potential vanilloid 5 channel (TRPV5) and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1).
  
  
  METHODS
  RAW264.7 cells were divided into two groups for treatment with RANKL for 5 days (group A) or with additional ZOL treatment in the last 2 days of RANKL treatment (group B). Osteoclastogenesis of the cells and the mRNA and protein expressions of TRPV5 and NFATc1 after the treatments were examined.
  
  
  RESULTS
  In group B, the number of newly generated osteoclasts (≥ 3 nuclei), number and size of dentin resorption lacunaes were 29.0 ± 2.4, 24.8 ± 1.1, and 2 030.0 ± 165.7 µm², respectively, which were significantly lower than those in group A (56.5 ± 4.5, 49.3 ± 0.9, and 3 946.7 ± 367.5 µm², respectively, P<0.01). Fluorescent intensity of TRPV5 and NFATc1 were also significantly decreased in group B (P<0.01). Compared with those in group A, TRPV5 mRNA and protein expressions in group B were down-regulated by 50.4% and 37.8%, and those of NFATc1 by 68.0% and 48.4%, respectively (P<0.01).
  
  
  CONCLUSIONS
  ZOL can significantly inhibit osteoclastogenesis and bone resorption, which may be attributed, at least partly, to ZOL-induced inhibition of TRPV5 and NFATc1 expressions.
authors.affiliation: College of Stomatology, Hebei United University, Tangshan 063000, China. E-mail: ljsbest_517@sina.cn.
authors.forename: Jueshan
authors.initials: J
authors.lastname: Lin
authors.forename: Wei
authors.initials: W
authors.lastname: Dong
authors.forename: Peng
authors.initials: P
authors.lastname: Zhang
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Hong
authors.initials: H
authors.lastname: Sun
authors.forename: Mengchun
authors.initials: M
authors.lastname: Qi
mesh_terms: D000818:Animals; D001862:Bone Resorption; D015220:Calcium Channels / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D004164:Diphosphonates / Q000494:pharmacology*; D015536:Down-Regulation; D007093:Imidazoles / Q000494:pharmacology*; D051379:Mice; D050778:NFATC Transcription Factors / Q000378:metabolism*; D010010:Osteoclasts / Q000187:drug effects*; D053245:RANK Ligand / Q000494:pharmacology; D012333:RNA, Messenger; D050916:TRPV Cation Channels / Q000378:metabolism*; D000077211:Zoledronic Acid
chemical_list: D015220:Calcium Channels; D004164:Diphosphonates; D007093:Imidazoles; D050778:NFATC Transcription Factors; C494005:Nfatc1 protein, mouse; D053245:RANK Ligand; D012333:RNA, Messenger; D050916:TRPV Cation Channels; C492240:Trpv5 protein, mouse; D000077211:Zoledronic Acid